KYMR
Kymera Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$6.87B
P/E Ratio
—
EPS
$-3.58
Beta
2.06
52W High
$103.00
52W Low
$28.06
50-Day MA
$83.56
200-Day MA
$68.54
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Kymera Therapeutics Inc
Kymera Therapeutics, Inc., a biopharmaceutical company, is focused on discovering and developing new small molecule treatments that selectively break down disease-causing proteins by harnessing the body's own natural protein breakdown system. The company is headquartered in Watertown, Massachusetts.
Fundamentals
| Revenue (TTM) | $51.48M |
| Gross Profit (TTM) | $-283.00M |
| EBITDA | $-348.58M |
| Operating Margin | -244.90% |
| Return on Equity | -27.10% |
| Return on Assets | -17.20% |
| Revenue/Share (TTM) | $0.58 |
| Book Value | $19.42 |
| Price-to-Book | 4.60 |
| Price-to-Sales (TTM) | 133.51 |
| EV/Revenue | 126.47 |
| EV/EBITDA | -9.49 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 55.50% |
| Shares Outstanding | $82.26M |
| Float | $55.05M |
| % Insiders | 2.08% |
| % Institutions | 110.48% |
Historical Volatility
HV 10-Day
36.42%
HV 20-Day
36.33%
HV 30-Day
34.41%
HV 60-Day
39.25%
HV Rank
7.9%
Volatility is currently expanding
Analyst Ratings
Consensus ($118.27 target)
5
Strong Buy17
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 5/14/2026